The Norwegian Cancer Society (NCS) have established an investment fund for Norwegian oncology companies. With the promising development of VB10.16, Vaccibody’s therapeutic vaccine against HPV induced precancerous lesions, NCS has decided to place their first investment in Vaccibody.
NCS will invest 500,000 euros. For publication in Norwegian, see Dagens Næringsliv.
“We are very pleased to see that Vaccibody has fulfilled all investment criteria demanded by NCS and is very proud that we are the first company they are investing in. This investment is an important step toward the financing of our first-in-man study”, CEO Ole Henrik Brekke says in comment.
Read more on Vaccibody.
Read more on the NCS`s investment fund.